
|Videos|October 11, 2017
Dr. Loeb on the Impact of Additional Testing for Prostate Cancer
Author(s)Stacy Loeb, MD
Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.
Advertisement
Stacy Loeb, MD, assistant professor of Urology and Population Health at NYU Langone Health's Perlmutter Cancer Center, discusses the impact of different genomic tests for patients with prostate cancer.
Patients now have more testing options than before, states Loeb. Patients no longer need to rely on a single biopsy, as there are multiple tests which will help physicians determine the most beneficial treatment and management options for the patient.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































